Abstract 1846P
Background
Confronting breast cancer diagnosis, alongside with complex and challenging treatment procedures comprise an extremely stressful experience. Psychological resilience (PR) is the ability to maintain or restore normal functioning while facing the adversity, leading to better quality of life and preventing stress-related health conditions in cancer patients. We aimed to investigate the impact of early breast cancer (EBC) diagnosis on PR, distress and perception of health.
Methods
Case-controlled study included 50 newly diagnosed EBC patients and 67 women without breast cancer whose screening mammography was graded by Breast imaging-reporting and data system 1 and 2. The level of distress, perception of health and PR were assessed using the Depression Anxiety and Stress Scale 21, SF 36-Item Health Survey 1.0 and Connor-Davidson RISC-25 scale. EBC patients were questioned after confronting EBC diagnosis and before starting the treatment.
Results
The EBC patients reported deterioration of health, compared to previous year (t (df) 3,835, p<0.01), while there were no differences between groups related to general and emotional health. There was no significant statistical difference between groups regarding the levels of depression, anxiety and stress. Majority of the EBC patients and controls, 66% and 82%, had no symptoms of depression, while severe depression was noted in 10% and 3%, respectively. Around 78% EBC patients and 89% controls didn't show any anxiety. Still, 8% EBC patients and 4.5% controls were severely anxious, and 10% EBC and 4% controls were severely stressed. And finally, regarding resilience, EBC patients showed significantly higher levels of PR than healthy control (t(df) 2,530, p<0.05).
Conclusions
Confronting EBC diagnosis, possibly leads to activation of intra-individual coping mechanisms and dynamic processes of effective adaptation leading to higher PR levels of EBC patients compared with healthy controls. Further research of PR should be encouraged, by investigating the mechanisms that protect individuals and prevent stress-related health conditions, resilience research shifts a paradigm from a disease-oriented to health-oriented and focuses on mechanisms that prevent stress-related disorders.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1878P - Prevalence of burnout in GU oncologists in central Asia: BUCARE survey
Presenter: Oxana Shatkovskaya
Session: Poster session 05
1879P - Investigating the effect of family support on the mental health of patients with breast cancer
Presenter: Maryam Garousi
Session: Poster session 05
1880P - Cancer care: Psychoeducational intervention for first-year residents of a general hospital in northeastern Mexico
Presenter: Celia Beatriz Gonzalez-Alcorta
Session: Poster session 05
1991P - Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial
Presenter: Fenghuan Sun
Session: Poster session 05
1992P - A phase II safety and efficacy study of PM8002 (anti-PD-L1 x VEGF-A bispecific) combined with paclitaxel as a second-line therapy for small cell lung cancer (SCLC)
Presenter: Ying Cheng
Session: Poster session 05
1993P - Phase IIIb study of durvalumab plus platinum–etoposide in first-line treatment of extensive-stage small cell lung cancer (CANTABRICO): Safety results
Presenter: Maria Dolores Isla Casado
Session: Poster session 05
1994P - Carboplatin, etoposide, bevacizumab, and atezolizumab in patients with extensive-stage SCLC – GOIRC-01-2019 CeLEBrATE ML41241 trial
Presenter: Karim Rihawi
Session: Poster session 05
1995P - Long-term benefit of atezolizumab plus chemotherapy in extensive stage small cell lung cancer (ES-SCLC): Exploratory analysis from the IMfirst study
Presenter: Maria Rosario Garcia Campelo
Session: Poster session 05
1996P - The impact of an etoposide shortage on patients with extensive-stage small cell lung cancer (ES-SCLC): Results of a natural experiment
Presenter: Claire Browne
Session: Poster session 05
1997P - A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer
Presenter: Zhe-Hai Wang
Session: Poster session 05